

**MISSISSIPPI DIVISION OF MEDICAID  
DRUG UTILIZATION REVIEW (DUR) BOARD  
MINUTES OF THE MARCH 2, 2023 MEETING**

<b>DUR Board Roster: State Fiscal Year 2023 (July 1, 2022 – June 30, 2023)</b>	<b>Jun 2022</b>	<b>Sep 2022</b>	<b>Dec 2022</b>	<b>Mar 2023</b>
Joseph Austin, MD	NA	✓	✓	
Lauren Bloodworth, PharmD				
Terrence Brown, PharmD	✓	✓	✓	✓
Patrick Bynum, MD	✓	✓	✓	
Chrysanthia Davis, PharmD	NA	✓	✓	✓
Tanya Fitts, MD	✓	✓		
Jahanzeb Khan, MD	NA	✓	✓	✓
Ray Montalvo, MD		✓		✓
Holly Moore, PharmD	✓	✓	✓	✓
Kristi Phelps, RPh	NA	✓	✓	✓
Joshua Pierce, PharmD	✓	✓	✓	
Bobbie West, MD	NA	✓		✓
<b>TOTAL PRESENT**</b>	<b>7</b>	<b>11</b>	<b>8</b>	<b>7</b>

*\*\* Total Present may not be reflected by individual members marked as present above due to members who either resigned or whose terms expired being removed from the list.*

**Also Present:**

**Division of Medicaid (DOM) Staff:**

Dennis Smith, RPh, DUR Coordinator; Gail McCorkle, RPh, Clinical Pharmacist; Chris Yount, MA, PMP, Staff Officer – Pharmacy; Sue Reno, RN, Program Integrity;

**University of Mississippi School of Pharmacy - MS-DUR Staff:**

Eric Pittman, PharmD, MS-DUR Project Director; Kaustuv Bhattacharya, PhD, Research Assistant Professor; Claire Lin, Graduate Student;

**Change Healthcare Staff:**

Paige Clayton, PharmD, On-Site Clinical Pharmacist;

**Coordinated Care Organization (CCO) Staff:**

Jenni Grantham, PharmD, Director of Pharmacy, Magnolia Health; Heather Odem, PharmD, Director of Pharmacy - Mississippi, UnitedHealthcare Community & State; Trina Stewart, PharmD, Pharmacy Manager, Molina Healthcare;

**Gainwell Staff:**

Tricia Banks, PharmD, MS Clinical Pharmacist;

**Alliant Health Staff:**

Catherine Brett, MD, Quality Director, MS UM/QIO; Buddy Ogletree, PharmD, Pharmacist;

**Visitors:**

Shawn Headley, Gilead; Floyd Holmes, Lilly; John Lovegrove, Sunovion; Roberto Pedraza, Vertex; Michele Shirley, Indivior; Paul Whatley, Novo Nordisk; Gene Wingo, Biogen; Ryan Ball.

**Call to Order/Welcome:**

Dr. Brown called the meeting to order at 1:02 pm.

**OLD BUSINESS:**

Dr. Moore moved to approve the minutes from the December 2022 DUR Board Meeting, seconded by Dr. Davis, and unanimously approved by the DUR Board.

**Resource Utilization Review:**

Dr. Pittman presented the resource utilization report for December 2022. Dr. Pittman noted that MS-DUR continues to experience data transfer issues from Gainwell and is not receiving MCO encounter claims information. The included resource utilization reports contain claims information only for the fee-for-service program.

**NEW BUSINESS:**

**Update on MS-DUR Educational Interventions:**

Dr. Pittman provided an overview of all DUR mailings and educational notices that occurred between December 2022 – February 2023.

**Special Analysis Projects:**

**Determining an MCI Cut Score for Predicting Severe Maternal Morbidity**

Multiple factors have been shown to be associated with negative maternal outcomes. Specifically, from our studies in the Mississippi Medicaid population, we found that MCI, distance to delivery center, age, and race were all significantly associated with SMM events. This follow-up analysis determined that a pregnant beneficiary with a score of one or higher on the MCI was at a significantly greater risk of experiencing an SMM event.

The following recommendations were presented:

1. MS-DUR recommends DOM encourage providers utilize the MCI as a screening tool to help identify pregnant beneficiaries at risk of experiencing SMM events.
2. DOM is encouraged to explore opportunities to provide additional maternal care to those beneficiaries identified as being at an increased risk of experiencing SMM events.

*Following discussion, Dr. Montalvo made a motion to accept the recommendations, seconded by Ms. Phelps, and unanimously approved by the Board.*

### **Gene Therapy Agents and Identification of Potential Eligible Beneficiaries**

Gene therapies offer much needed treatment options in the rare disease landscape where effective treatments have been limited in the past. In light of these groundbreaking treatment advances, payers are tasked with identifying appropriate individuals eligible of receiving these therapies. Although the number of individuals identified as being eligible to receive these therapies may be small, the cost of some of these gene therapies can be astronomical requiring payers to plan and appropriately allocate resources to cover these products.

This report for the DUR Board was for information and discussion purposes only. No action was sought as a result of this report.

### **FDA Drug Safety Updates:**

Dr. Pittman noted there were no FDA drug safety communications between December 2022 – February 2023.

### **Pharmacy Program Update:**

Mr. Smith provided a pharmacy program update highlighting two items:

- Stay Covered – Medicaid has begun the process of re-qualifying Medicaid members. Mr. Smith stressed the importance of having Medicaid members update their contact information as soon as possible. This is especially important as Congress passed the Consolidated Appropriations Act (CAA) in December 2022. Under the CAA, continuous coverage conditions will expire, and states will resume routine eligibility operations this spring.
- Late Breaking News – Mr. Smith encouraged all Medicaid providers to sign-up for email alerts that are distributed when DOM posts a Late Breaking News update.

### **Next Meeting Information:**

The next Board meeting is scheduled for June 15, 2023.

Dr. Brown adjourned the meeting at 2:21 pm

Submitted,

Eric Pittman, PharmD  
Evidence-Based DUR Initiative, MS-DUR

**Meeting Location:** Woolfolk Building, 501 North West Street, Conference Room 145, Jackson, MS 39201, unless otherwise noted by the corresponding date of the meeting listed below.

**Contact Information:** Office of Pharmacy:

Chris Yount, 601-359-5253; [Christopher.yount@medicaid.ms.gov](mailto:Christopher.yount@medicaid.ms.gov), or  
Jessica Tyson, 601-359-5253; [jessica.Tyson@medicaid.ms.gov](mailto:jessica.Tyson@medicaid.ms.gov)

Notice details:

**State Agency:** MS Division of Medicaid

**Public Body:** Drug Utilization Board (DUR) Meeting

**Subject:** Quarterly Meeting

**Dates and Times:**

2023 dates:

- March 2, 2023 (1-3pm; Room 117, Woolfolk Building)
- June 15, 2023 (1-3pm; Room 145)
- September 7, 2023 (1-3pm; Room 145)
- December 7, 2023 (1-3pm; Room 145)

**Description:** The Mississippi Division of Medicaid's Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for physicians, pharmacists, and the beneficiary. The Drug Utilization Review (DUR) Board is composed of twelve participating physicians and pharmacists who are active MS Medicaid providers and in good standing with their representative organizations.

The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

The Drug Utilization Review (DUR) Board meets quarterly.

## Meetings

Meetings will be held at 1:00 pm in Woolfolk Building Room 145 unless otherwise noted. 2023 dates are as follows:

- March 2, 2023 (Room 117, Woolfolk Building – no virtual options, live meeting);
- June 15, 2023 (Room 145, Woolfolk Building);
- Sept. 7, 2023 (Room 145, Woolfolk Building),
- Dec. 7, 2023 (Room 145, Woolfolk Building)

**Important Updates:** Beginning October 1, 2021, pharmaceutical and industry members, vendors, and general public must register to attend. Registration will open thirty (30) days prior to the meeting date. Registration will close at 12pm (noon) the day before the meeting. Due to the ongoing pandemic, *only one representative per company may register/attend*. Public speaking is not allowed at DUR meetings unless called on by the Board.

**Parking:** parking may be found on the perimeter of the Woolfolk Building, on the north side of the Woolfolk Building located at the old Wright and Ferguson building (yellow/brown building), and at the Division of Medicaid and First Baptist Church main parking lots at the corner of High Street and North President Street. *Guests may not park at the Woolfolk Building or in any parking space marked "Reserved".*

 **CLICK HERE to register online for the March 2, 2023 DUR Board meeting!**

**Note: as of 2/14/2023, registration limit (seating capacity for meeting room) has been reached.**

NOTE: Registration is **required** for all pharmaceutical industry and advocacy representatives to be able to attend DUR Board meetings.

**Note: as of 2/14/2023, registration limit (seating capacity for meeting room) has been reached.**

Companies that have met the one (1) representative per company limit (as of 2/23/2023):

1. Alliant
2. Gainwell
3. Gilead
4. Indivior
5. Lilly
6. Magnolia
7. Molina
8. Novartis
9. Novo Nordisk
10. Provention Bio
11. Regeneron
12. Spark Therapeutics
13. Sunovion
14. UHC
15. Vertex
16. Viking Healthcare Solutions